All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F08%3A00103096" target="_blank" >RIV/00843989:_____/08:00103096 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1007/s00415-007-0733-2" target="_blank" >http://dx.doi.org/10.1007/s00415-007-0733-2</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s00415-007-0733-2" target="_blank" >10.1007/s00415-007-0733-2</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

  • Original language description

    Background The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and >= 2 clinically silent brain MRI lesions. Methods Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176) were created for demographics, clinical, laboratory, and MRI findings at onset. The 'natural' risk of clinically definite MS (CDMS) over 2 years was estimated by Kaplan Meier statistics in placebo-treated patients; the IFNB-1b treatment effect was analysed by Cox proportional hazards regression. Results The risk of CDMS was increased in placebotreated patients (overall 45 %) if they were younger (< 30 years: 60%), were cerebrospinal fluid (CSF)-positive (49 %), or had received steroid treatment (48 %). MRI parameters implied a higher risk in placebo-treated patients with >= 9 T2-lesions (48%) or >= 1 gadolinium (Gd)-enhancing lesions (52 %). The CDMS risk was highest (75 %) in placebo-treated patients with monofocal disease onset displaying MRI di

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FH - Neurology, neuro-surgery, nuero-sciences

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2008

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of neurology

  • ISSN

    0340-5354

  • e-ISSN

  • Volume of the periodical

    255

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    8

  • Pages from-to

    480-487

  • UT code for WoS article

    000255255300002

  • EID of the result in the Scopus database